Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 141

1.

Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis.

Liu M, Mo QG, Wei CY, Qin QH, Huang Z, He J.

Oncol Lett. 2013 Mar;5(3):983-991. Epub 2012 Dec 28.

2.

Platinum-based chemotherapy in triple-negative advanced breast cancer.

Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Peña-Curiel O, Baez-Revueltas B, Kiss A, Kassam F, Enright K, Verma S, Pritchard K, Myers J, Dent R.

Breast Cancer Res Treat. 2014 Aug;146(3):567-72. doi: 10.1007/s10549-014-3033-4. Epub 2014 Jul 8. Erratum in: Breast Cancer Res Treat. 2015 Apr;150(3):697.

PMID:
25001611
3.

Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis.

Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z.

Mol Clin Oncol. 2015 May;3(3):720-724. Epub 2015 Feb 26.

5.

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.

6.

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression.

Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N.

Oncol Lett. 2014 Mar;7(3):866-870. Epub 2014 Jan 7.

7.

Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.

Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH.

Int J Cancer. 2009 Mar 15;124(6):1457-62. doi: 10.1002/ijc.24090.

8.

Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer.

Tang Y, Zhu L, Li Y, Ji J, Li J, Yuan F, Wang D, Chen W, Huang O, Chen X, Wu J, Shen K, Loo WT, Chow LW.

J Transl Med. 2012 Sep 19;10 Suppl 1:S4. doi: 10.1186/1479-5876-10-S1-S4. Epub 2012 Sep 19.

9.

Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.

Yagata H, Kajiura Y, Yamauchi H.

Breast Cancer. 2011 Jul;18(3):165-73. doi: 10.1007/s12282-011-0254-9. Epub 2011 Feb 3. Review. Erratum in: Breast Cancer. 2012 Oct;19(4):369.

PMID:
21290263
10.

The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.

Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S.

Breast Cancer Res Treat. 2014 Apr;144(2):223-32. doi: 10.1007/s10549-014-2876-z. Epub 2014 Feb 21. Review.

PMID:
24557340
11.

Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.

Shinde AM, Zhai J, Yu KW, Frankel P, Yim JH, Luu T, Kruper L, Vito C, Shaw S, Vora NL, Kirschenbaum M, Somlo G.

Breast. 2015 Feb;24(1):18-23. doi: 10.1016/j.breast.2014.10.008. Epub 2014 Nov 20.

12.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2008 Mar 10;26(8):1275-81. doi: 10.1200/JCO.2007.14.4147. Epub 2008 Feb 4.

PMID:
18250347
13.

Triple-negative breast cancer: role of specific chemotherapy agents.

Isakoff SJ.

Cancer J. 2010 Jan-Feb;16(1):53-61. doi: 10.1097/PPO.0b013e3181d24ff7. Review.

14.

Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis.

Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z.

Oncol Lett. 2015 Jun;9(6):2825-2832. Epub 2015 Mar 26.

15.

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy.

Wu K, Yang Q, Liu Y, Wu A, Yang Z.

World J Surg Oncol. 2014 Apr 15;12:95. doi: 10.1186/1477-7819-12-95.

16.

Platinum-based chemotherapy in metastatic triple negative breast cancer: Experience of a tertiary referral centre in India.

Maka VV, Panchal H, Shukla SN, Talati SS; Department of Medical Oncology Gujarat Cancer and Research Institute Ahmedabad Gujarat India.

Gulf J Oncolog. 2015 Jan;1(17):52-7.

PMID:
25682453
17.

Systemic treatment strategies for triple-negative breast cancer.

Yadav BS, Sharma SC, Chanana P, Jhamb S.

World J Clin Oncol. 2014 May 10;5(2):125-33. doi: 10.5306/wjco.v5.i2.125. Review.

18.

Impact of triple-negative breast cancer phenotype on prognosis in patients with stage I breast cancer.

Kim JE, Ahn HJ, Ahn JH, Yoon DH, Kim SB, Jung KH, Gong GY, Kim MJ, Son BH, Ahn SH.

J Breast Cancer. 2012 Jun;15(2):197-202. doi: 10.4048/jbc.2012.15.2.197. Epub 2012 Jun 28.

19.

[Comparison of the effectiveness of platinum-based chemotherapy versus non-platinum-based chemotherapy for triple-negative breast cancer with metastases confined to the lungs].

Hong R, Ma F, Shi X, Li Q, Zhang P, Yuan P, Wang J, Fan Y, Cai R, Li Q, Xu B.

Zhonghua Zhong Liu Za Zhi. 2014 Oct;36(10):788-92. Chinese.

PMID:
25567313
20.

Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.

Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O, Shen KW.

PLoS One. 2014 Sep 23;9(9):e108405. doi: 10.1371/journal.pone.0108405. eCollection 2014.

Supplemental Content

Support Center